Meta Analysis Of Tumour Remission Of Hormone Receptor Positive Breast Cancer After Neoadjuvant Endocrine Therapy

Objective:Objective to investigate the effects of neoadjuvant endocrine therapy(NET)and neoadjuvant chemotherapy(NCT)on tumor remission in patients with hormone receptor(HR)positive breast cancer,including pathological complete response(pCR),complete remission(CR)and partial remission(PR).Methods:Search PubMed,EMBASE,Cochrane Library,VIP Database,CNKI(China National Knowledge Infrastructure)for qualified tests from the databases set up to February 2022.Revman5.3 software for fixed or random effect model meta-analysis.Results:11 eligible clinical trials data were analyzed.There were 21414 HR positive breast cancer patients.The results of meta-analysis showed that CR + PR [OR = 0.66,(95% CI,0.40 ～ 1.07),P = 0.09],the difference was not statistically significant(P > 0.05),breast tumor pCR [OR = 0.42,(95% CI,0.22 ～ 0.79),P = 0.007],the difference was statistically significant(P < 0.05),axillary pCR [OR = 0.34,(95% CI,0.18 ～ 0.64),P = 0.001],the divergence was statistically meaning(P < 0.05),There was no difference in the ability of CR + PR between NET group and NCT group,The ability to improve breast and axillary pCR was lower than that of NCT group.BCS [OR = 1.46,(95% CI,0.96 ～ 2.22),P = 0.08],the divergence was not statistically meaning(P > 0.05).The ability of NET group and NCT group in improving br east conserving surgery rate was the same.Conclusion:The CR+PR of ER positive breast cancer patients after NET was not different from that after NCT.The pCR rate of breast and axillary after NET was lower than that of NCT,and there was no difference in breast conserving surgery rate.